Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma

Author:

Xuan Wenjing1,Hsu Wen-Hao2,Khan Fatima1ORCID,Dunterman Madeline1,Pang Lizhi1,Wainwright Derek A.1ORCID,Ahmed Atique U.1ORCID,Heimberger Amy B.1ORCID,Lesniak Maciej S.1ORCID,Chen Peiwen1ORCID

Affiliation:

1. 1Department of Neurological Surgery, Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

2. 2Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Abstract

Abstract The symbiotic interactions between cancer stem cells and the tumor microenvironment (TME) are critical for tumor progression. However, the molecular mechanism underlying this symbiosis in glioblastoma (GBM) remains enigmatic. Here, we show that circadian locomotor output cycles kaput (CLOCK) and its heterodimeric partner brain and muscle ARNT-like 1 (BMAL1) in glioma stem cells (GSC) drive immunosuppression in GBM. Integrated analyses of the data from transcriptome profiling, single-cell RNA sequencing, and TCGA datasets, coupled with functional studies, identified legumain (LGMN) as a direct transcriptional target of the CLOCK–BMAL1 complex in GSCs. Moreover, CLOCK-directed olfactomedin-like 3 (OLFML3) upregulates LGMN in GSCs via hypoxia-inducible factor 1-alpha (HIF1α) signaling. Consequently, LGMN promotes microglial infiltration into the GBM TME via upregulating CD162 and polarizes infiltrating microglia toward an immune-suppressive phenotype. In GBM mouse models, inhibition of the CLOCK–OLFML3–HIF1α–LGMN–CD162 axis reduces intratumoral immune-suppressive microglia, increases CD8+ T-cell infiltration, activation, and cytotoxicity, and synergizes with anti–programmed cell death protein 1 (anti–PD-1 therapy). In human GBM, the CLOCK-regulated LGMN signaling correlates positively with microglial abundance and poor prognosis. Together, these findings uncover the CLOCK–OLFML3–HIF1α–LGMN axis as a molecular switch that controls microglial biology and immunosuppression, thus revealing potential new therapeutic targets for patients with GBM.

Funder

NIH

DoD Career Development Award

American Cancer Society Institutional Research Grant

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Immunology

Reference52 articles.

1. Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma;Khosla;Ann Transl Med,2016

2. The somatic genomic landscape of glioblastoma;Brennan;Cell,2013

3. Comprehensive genomic characterization defines human glioblastoma genes and core pathways;Cancer Genome Atlas Research Network;Nature,2008

4. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

5. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era;McNamara;J Neurooncol,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3